CA
NZ
UK
AU
IND
US
Bristol Myers Squibb reported second-quarter revenues of $13.0 billion, marking a 6% increase over the previous year. This growth has been significantly bolstered by a 15% rise in earnings from its Growth Portfolio, which totaled $7.6 billion. The impressive figures are indicative of the …
The cyclospora outbreak has reached unprecedented levels, marking the largest outbreak on record. With questions emerging about the outbreak's potential to last longer than previous instances, which typically resolved by August, stakeholders in food supply and safety are on high alert. This situation poses …
Daiichi Sankyo Company, Limited recently conducted its earnings call for the first quarter of fiscal year 2026. Management detailed the company’s strategic focus on enhancing its presence in various therapeutic areas, particularly oncology. This focus is poised to improve its market position amid competitive …
Q2 Results Indicate Strong Performance
Anteris Technologies Global Corp. (NASDAQ: AVR) is facing scrutiny following the issuance of 44,068 CHESS Depositary Interests (CDIs) on July 10, 2026, which occurred amid an administrative oversight regarding a required cleansing notice. This incident has drawn attention as it raises compliance questions, although …
The news sparked investor concerns about the potential impact of the deal on AstraZeneca's future. This earnings beat may be overshadowed by the merger talks, as investors weigh the potential benefits and risks of the deal, which could lead to increasedVolatilityin the company's shares.
Beyond Air, Inc. (NASDAQ: XAIR) has successfully secured approximately $10.2 million through a private placement of stock and warrants. The deal is set to close on July 31, 2026, providing essential capital for ongoing operations and development initiatives.
Braveheart Bio is preparing for a $300 million initial public offering, a substantial infusion ofCapitalthat can accelerate growth and attract strategic partners. This influx of funds matters to investors as it will enable the company to advance its clinical programs and expand its research …
BrightSpring Health Services delivered a strong Q2 2026 performance, slashing $300 million of debt while posting $206 million of adjusted EBITDA and $87 million of net income. Analysts noted that the balance‑sheet improvement reduces refinancing risk and may support higherDividendpayouts or strategic acquisitions as …
Novo Nordisk experienced a dramatic 9% decline in its share price as news broke that the experimental heart medicine ziltivekimab did not achieve its intended efficacy inClinical Trials. This event marks a critical turning point for Novo Nordisk, which has heavily invested in its …
Please wait processing your request...